Navigation Links
3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
Date:2/10/2011

MENLO PARK, Calif., Feb. 10, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer.  

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"Steve's contributions have been pivotal as a member of the team during his tenure at 3-V," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer.  "I look forward to working with him as we continue to build the 3-V team and advance the company's programs."

Mr. Brady joined the 3-V team in 2010 as Vice President, Corporate Development, Strategy & Operations, with management responsibility for the company's business functions, including strategy, finance and legal.  Prior to joining the company, Mr. Brady was the Vice President of Corporate Development of Proteolix, Inc. where he had primary responsibility for Proteolix's business development activities, resulting in the sale of the company to Onyx Pharmaceuticals, Inc.  Previously, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capacities. Prior to his tenure with Lexicon Pharmaceuticals, Inc., Mr. Brady was a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co., LLC, and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.  Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from the New York University School of Law.

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel therapeutics that target host cell factors required for infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationMerdad V. Parsey, MD, PhDChief Executive Officer650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
3. DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3
4. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
5. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
6. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
7. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
8. Ambit Biosciences Initiates Two Phase I Clinical Trials
9. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
10. Cell Biosciences Announces US Patent Issuance
11. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... TAMPA, Fla. , Feb. 22, 2017  Corin ... Shoulder System, a device used to treat patients with ... form of shoulder arthritis. The condition, known as cuff ... arm and shoulder. The Humelock Reversed ... privately-held upper extremities technology company based near ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Pipeline Review, 2016" report to their offering. ... Dermatological conditions ... and approximately one-third of the US population suffers from at ... majority of the dermatology market has remained saturated with established ...
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By ... Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering. ... The ... growth during 2016-2022 This report provides a detailed ...
Breaking Medicine Technology:
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine ... a small number of neurosurgeons in Michigan performing minimally invasive back surgery that ...
(Date:2/22/2017)... ... ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: The ... PM ET. A recording of the webinar will also be made available following its ... want to find out what really happened in the seniors housing and care merger ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
(Date:2/22/2017)... OAKLAND/SAN FRANCISCO BAY AREA - NORTHERN CALIFORNIA (PRWEB) , ... ... ... Forum (PMF) aims to expand the pipeline and the number of African ... support that encourages medical students and residents to pursue their careers as physicians ...
Breaking Medicine News(10 mins):